Evidence map›Paper›PMID 41475977›Full record

ArticleGut2026

GSK3β

Muhammad Umair Latif, Xueang Liu, Aiko Bockelmann, Laura Huhnold, Geske Elisabeth Schmidt, Lukas Klein, Xueyuan Zhao, Lena-Christin Conradi, Karly Conrads, Anna Lena Weber and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Muhammad Umair LatifDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Xueang LiuDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Aiko BockelmannDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Laura HuhnoldDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Geske Elisabeth SchmidtDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Lukas KleinDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.ORCID http://orcid.org/0000-0003-3725-068X
Xueyuan ZhaoDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Lena-Christin ConradiGeneral and Visceral Surgery, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Karly ConradsClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Anna Lena WeberDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Sercan MercanDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Kristina ReutlingerDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Atmika PaulClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Zeynab NajafovaRobert Bosch Centre for Tumour Diseases, Stuttgart, BW, Germany.
Steven A JohnsenRobert Bosch Centre for Tumour Diseases, Stuttgart, BW, Germany.ORCID http://orcid.org/0000-0003-1198-5805
Zuriñe Bonilla Del RioDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Frederike PenzDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Jovan TodorovicClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Holger BastiansDepartment for Molecular Oncology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Tim BeissbarthDepartment of Medical Bioinformatics, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Ulrich SaxClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Ramy AshryInstitute of Toxicology, University Medical Center Mainz, Mainz, Germany.
Oliver H KrämerInstitute of Toxicology, University Medical Center Mainz, Mainz, Germany.
Elisabeth HessmannDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Günter SchneiderClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Philipp StroebelClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.
Ivan BogeskiMolecular Physiology, Institute of Cardiovascular Physiology, University Medical Center Göttingen, Gottingen, Niedersachsen, Germany.
Shiv K SinghDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany.ORCID http://orcid.org/0000-0002-5725-4058
Volker EllenriederDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Lower Saxony, Germany volker.ellenrieder@med.uni-goettingen.de.ORCID http://orcid.org/0000-0001-9981-8571

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of pharmacological glycogen synthase kinase-3β (GSK3β) inhibition is currently being investigated in unselected cohorts of metastatic pancreatic ductal adenocarcinoma (PDAC). Here, we sought to determine the clinical significance of nuclear GSK3β accumulation in patients with resectable PDAC.

objectiveThis study aimed to explore the therapeutic potential and underlying mechanisms of GSK3β pathway disruption in PDAC with enriched nuclear GSK3β levels.

designWe investigated the activation and function of GSK3β and its downstream transcription factor NFATc1 in tumour recurrence, growth and resistance using human PDAC tissues, patient-derived organoids and tumour cells, PDAC explants, cell lines and murine models. GSK3β signalling was disrupted using genetic and pharmacological approaches. Live-cell imaging, proliferation, homologous recombination (HR) repair and comet assays, messenger RNA sequencing and chromatin immunoprecipitation were used to explore GSK3β-NFATc1 signalling-mediated target gene regulation in DNA repair, growth and resistance.

resultsNuclear GSK3β accumulates in a subset of resected PDAC and promotes proliferation and DNA repair through NFATc1. The GSK3β

conclusionWe have identified a highly aggressive GSK3β

Indexed as

Carcinoma, Pancreatic DuctalDrug Resistance, NeoplasmGlycogen Synthase Kinase 3 betaNFATC Transcription FactorsPancreatic NeoplasmsRecombinational DNA RepairAnimalsCell Line, TumorCell ProliferationCisplatinFemaleGene Expression Regulation, NeoplasticHumansMiceSignal TransductionCisplatinGlycogen Synthase Kinase 3 betaGSK3B protein, humanNFATC1 protein, humanNFATC Transcription FactorsCANCERCELL DEATHDNA DAMAGEDRUG RESISTANCEPANCREATIC CANCER

Identifiers

PMID41475977
PMCPMC13422050

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.